肿瘤靶向给药系统的研究进展
作者：黄园;袁芳;张志荣;
Author：
收稿日期： 年卷（期）页码：2006,(06):-566-569
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：肿瘤;靶向;给药系统;增强的透过及滞留效应;长循环原理
Key words：
基金项目：
中文摘要
综述了肿瘤组织靶向、肿瘤细胞靶向、肿瘤血管靶向等给药系统及肿瘤靶向治疗基因给药系统的研究进展,以完善现有肿瘤的靶向治疗。
参考文献
[1]Maeda H.Tumor vascu lar perm eab ility and the EPR effect inmacromolecu lar therapeutics:a review[J].J Contr Releas,2000,65:271-282.
[2]Maeda H,Scymour LM,M iyamoto Y,et a.l Con jugates of anti-cancer agents and polym ers:advantage of macromolecu lar thera-peutics in vitro[J].B iocon jug Che,1992,3:351-362.
[3]Bukowsk i R.Pegylated interferon alfa-2b treatm ent for patientsw ith solid tumors:a phase I/II study[J].J of C li Oncolo,2002,20:3841-3851.
[4]Anatoly NL,Vladim ir PT.M icelles from lipid derivatives ofwater-solub le polym ers as delivery system s for poorly solub le drugs[J].Adv D rug D eliv Rev,2004,56:1273-1289.
[5]张志荣.靶向治疗分子基础与靶向药物设计[M].北京:科学出版社,2005.223,237,250.
[6]颜秋平.肿瘤特异靶向性药物载体的研究进展[J].国外医学药学分册,2005,32(3):151-155.
[7]刘海峰.肿瘤靶向治疗[J].第三军医大学学报,2003,25(16):1491.
[8]Peppas LB,B lanchette JO.Nanoparticle and targeted system s forcancer therapy[J].Adv D rug D eliv Rev,2004,56:1649-1659.
[9]Christopher PL,Joseph AR.Folate-targeted chemotherapy[J].Adv D rug D eliv Rev,2004,56:1127-1141.
[10]Yoo H S,Park T G.Folate receptor targeted b iodegradab le poly-m eric doxorub icin m icelles[J].J of Contr Releas,2004;96:273-283.
[11]TanseyW,Ke S,Cao X-Y,et al.Synthesis and characteriza-tion of branched poly(L-glutam ic acid)as a b iodegradab le drugcarrier[J].J of Contr Releas,2004,94:39-51.
[12]Leamon CP,Reddy JA.Folate-targeted chemotherapy[J].AdvD rug D eliv Rev,2004,56:1127-1141.
[13]欧晓红,匡安仁.靶向治疗中胰岛素的载体作用[J].生物医学工程杂志,2000,17(1):87-92.
[14]L iu W S,Huang Y,Zhang ZR.Synthesis and characterization ofthe tumor targeting m itoxantrone-insu lin con jugate[J].Arch ivesof Pharmacal Res,2003,26(11):892-897.
[15]Ish ida O,Mamyama K,Tanahash i H,et al.L iposom es bearingpolyethyleneglyco-coupled transferrin w ith intracellu lar targe-ting property to the solid tun lor[J].Pharmac Res,2001,l8(7):1042.
[16]Asche C,Dumy P,Carrez D l.N itrobenzylcarbamate prodrugs ofcytotoxic acrid ines for potential use w ith n itroreductase gene-d i-rected enzym e prodrug therapy[J].B ioorg m ed che lett,2006;16:1990-1994.
[17]Satch i R,Connors TA,Duncan R.PDEPT:polym er-d irectedenzym e prodrug therapy I.HPMA copolym er-cathepsin B andPK1 as a model comb ination[J].British J Cancer,2001,28:11-17.
[18]Kojima H,Iida M,M iyazak i H,et al.Enhancem ent of cytara-b ine sensitivity in squamous cell carcinoma call line transfected-w ith deoxycytid ine k inase[J].Arch ives of O tolaryngol HeadNeck Surgery,2002,128(6):708-712.
[19]Janssen APCA,Sch iffelers RM,Ten Hagenet TLM,et al.Pep-tide-targeted PEG-liposom es in anti-angiogen ic therapy[J].Int J Pharmac,2003,254(1):55-58.
[20]童强,王国斌,卢晓明,等.血管内皮生长因子一阿霉素脂质体的制备及体外靶向杀伤肿瘤血管内皮细胞的研究[J].中华实验外科杂志,2005,22(3):313-316.
[21]朱晓东.肿瘤新生血管相关内皮细胞受体研究进展[J].生命科学,2001,13(4):177-180.
[22]孙厚良,曾昭淳.整合素与血管生成的负调节[J].中华实用医学,2004,6(8):68-70.
[23]Astrid J Schraa,Robbert JKok,Berendsen AD,et al.Endotheli-al cells internalize and degrade RGD-mod ified proteins devel-oped for tumor vascu lature targeting[J].J Contr Releas,2002,83(2):241-251.
[24]熊小兵,黄悦,吕万良,等.RGD类似物修饰的阿霉素隐形脂质体的制备及体外细胞结合试验[J].药学学报,2005,40(12):1085-1090.
[25]张妮娜.肿瘤血管生成抑制药物研究现状与展望[J].实用肿瘤学杂志,2004,18(3):231-233.
[26]Ogris M,W alker G,B lessing T,et a.l Tumor-targeted genetherapy:strategies for the preparation of ligand-polyethyleneglycol-polyethylen im ine/DNA complexes[J].J Contr Releas,2003,91(1):173-181.
[27]Hood JD,Bednarsk i M,Frausto R,et a.l Tumor regression bytargeted gene delivery to the neovascu lature[J].Science,2002,296:2404-2410.
【关闭】
